Printer Friendly

COMPANY INFORMATION
Isotechnika Pharma Inc. 5120 75 St Edmonton, AB T6E 6W2 Tel: (780) 487-1600 Toll-free: (888) 487-9944 Fax: (780) 484-4105 Contact Name Dennis Bourgeault Industry Biotechnology		Key Executives Robert T. Foster, CEO Dennis Bourgeault, CFO Discovers, develops and plans to commercialize immunosuppressive therapeutic drugs for the treatment of autoimmune diseases and for use in the prevention of organ rejection in transplantation. Also develops and sells diagnostic products and services.
FP ADVISOR COVERAGE Isotechnika Pharma Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • FP Investor Reports • FP Predecessor & Defunct • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/ISA $0.24 $0.30 $0.11 n.a. n.a. n.a. 1.22 Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 187,264 n.a. $-0.10 Sept. 30/09 113.64% -48.5% -36.41% $30,859
ANNUAL FINANCIALS Periods ended: 12m Dec. 31/08 12m Dec. 31/07 12m Dec. 31/06 $000s $000s $000s Operating revenue 4,718 2,312 4,106 Net income (19,328) (33,494) (26,637) Total assets 32,443 42,253 35,710 $ $ $ Earnings per share* (0.18) (0.32) (0.32) % % % Return on equity (102.49) (129.71) (73.28)   * Common
TRAILING 12-MONTH VALUES Periods ended: Sept. 30/09 Sept. 30/08 $000s $000s Operating revenue 3,274 4,611 Net income (11,245) (22,941) $ $ Earnings per share (0.09) (0.22)

COMPANY NEWS

Results for 'Isotechnika Pharma Inc.' from past 30 days: No hits. (Links are to articles.)